Constantiam Biosciences

Constantiam Biosciences is developing CB-001, a first-in-class oral, CNS-penetrant allosteric chaperone for neuronopathic Gaucher Disease & GBA-Parkinson's.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded September 2020
  • Employees 4
  • Incorporation Type C-corp
  • Website constantiambio.com

Only investors on Gust who have been granted access can view this content.

Interested in this startup? Sign In or Sign Up to request more information.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free